Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® , IMFINZI® , chemotherapy and bevacizumab demonstrated a... | June 3, 2023
First global Phase III trial of immunotherapy and chemotherapy combination to demonstrate clinical benefit in this setting Trial will continue to assess event-free survival ... | June 10, 2023
FinancialContent fully hosted finance channel
Using propensity score matching in a US nationally representative sample, authors found the effect of nonadherence to diabetes guidelines on health care expenditures of patients with diabetes.